```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Skeletal Dysplasia Treatment market with a 42% share, driven by expedited orphan-drug approvals, concentrated academic referral centers, and payers willing to reimburse >$500k annual C-type natriuretic peptide analog costs. The 2023 U.S. "Achieving Equity in Rare Bone Disorders" mandate accelerates newborn sequencing, underpinning regional forecast CAGR of 9.1%."
},
{
"type": "list",
"title": "Key regional drivers",
"items": [
{ "text": "Europe (28% share) leverages cross-border EMA PRIME designations and pooled EU4Health budgets; adoption varies with heterogenous HTA thresholds.", "level": 1 },
{ "text": "Asia Pacific (18%) is the fastest-growing region (11.4% CAGR) as Japan’s premium pricing corridor, China’s NHSA fast-track, and India’s 100-day genomic medicine program shorten access gaps for ultra-rare therapies.", "level": 1 },
{ "text": "Latin America (7%) shows public tenders for growth-modulating surgery implants, yet import duties cap penetration below 5% of eligible patients.", "level": 1 },
{ "text": "Middle East & Africa (5%) is catalyzed by Saudi & UAE sovereign rare-disease funds, though limited multidisciplinary skeletal dysplasia centers constrain Skeletal Dysplasia Treatment market growth to high-net-worth cohorts.", "level": 1 }
]
},
{
"type": "paragraph",
"content": "Collectively, demographic expansion of achondroplasia births and policy-backed newborn screening will reshape regional forecast shares toward Asia Pacific beyond 2028."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 42 },
{ "name": "Europe", "value": 28 },
{ "name": "Asia Pacific", "value": 18 },
{ "name": "Latin America", "value": 7 },
{ "name": "Middle East & Africa", "value": 5 }
]
}
}
```
